Prima Biomed Ltd. (PBMD) - Earnings & Price History

PBMD: Prima Biomed Ltd. - 2.12, $52.35M, -0.08 (-3.64%)

Sector: Healthcare - Industry: Biotechnology

Prima BioMed Ltd. engages in the research, development, and commercialization of medical biotechnology products in Australia. The company develops immunotherapeutic products for the treatment of various types of cancer. Its core technologies are based on the LAG-3 immune control mechanism, which plays a vital role in the regulation of the T cell immune response. The companys lead product candidate is IMP321, a recombinant protein, which is in Phase IIb clinical trials in metastatic breast cancer when used as a chemo-immunotherapy, as well as in Phase I clinical trials in metastatic melanoma. Its other products include IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company is also developing CVac, an autologous dendritic cell-based product through Phase II cl

Past PBMD reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume

Login | Register
Tuesday Jun 18, 2019   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR


index chart
index color